Prolonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics

Morgan Stanley analyst Michael Ulz has maintained their bearish stance on YMAB stock, giving a Sell rating yesterday.

Michael Ulz has given his Sell rating due to a combination of factors including the extended timelines for Y-Mabs Therapeutics’ SADA platform development. Although the company has shown progress with favorable safety profiles and tumor uptake in their Phase 1 Part A results, the need for further optimization and a bridging study delays the availability of Part B data until the second half of 2027.
While the optimization of the GD2-SADA program is promising, the prolonged timeline limits the potential for near-term catalysts, which impacts the stock’s attractiveness. Additionally, the updated strategy for targeting additional cancers such as lung, women’s, and gastrointestinal cancers, while positive, does not offset the concerns regarding the extended development timeline.

In another report released yesterday, Bank of America Securities also maintained a Sell rating on the stock with a $3.00 price target.

YMAB’s price has also changed dramatically for the past six months – from $11.880 to $4.620, which is a -61.11% drop .